Director, CMC Quality Control & Quality Assurance

At HAYA Therapeutics, we are revolutionizing RNA-guided genome-targeting therapies to treat fibrosis, heart failure, and other serious diseases associated with aging. Our innovative platform leverages long non-coding RNAs (lncRNAs)—key regulators within the “dark matter” of the genome—to develop first-in-class, highly specific therapies that modulate gene expression and restore cellular function. 

Recognized for our innovation, HAYA received the prestigious Innosuisse Certificate for Sustainable Growth and has been nominated as TOP Innovative Companies in Switzerland 2025. As a fast-growing biotech, we offer an entrepreneurial, science-driven environment where you’ll have a direct impact on shaping our pipeline and advancing RNA medicine.

1.     Purpose:

Define and execute phase-appropriate Quality Control and Quality Assurance strategies for antisense oligonucleotide (ASO) programs across external manufacturing networks to ensure robust cGMP compliance and accelerate pipeline progression from discovery through clinical development.